Home > Healthcare > Medical Devices > Diagnostic Devices > Pulmonary Fibrosis Biomarkers Market

Pulmonary Fibrosis Biomarkers Market Share

Report ID: GMI8456
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Pulmonary Fibrosis Biomarkers Market Share

The pulmonary fibrosis biomarkers industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. Companies are developing innovative biomarkers to aid in disease diagnosis, prognosis, and treatment monitoring. These biomarkers range from genetic markers to protein expression profiles, reflecting the complex nature of pulmonary fibrosis. Key factors driving competitiveness include the accuracy, specificity, and reproducibility of biomarkers, as well as their potential to guide personalized treatment strategies. Regulatory approvals and collaborations with research institutions further influence market positioning.

Pulmonary Fibrosis Biomarkers Market Companies

Some of the eminent market participants operating in the pulmonary fibrosis biomarkers industry include:

Biocartis NV
Biogen Inc
Bristol-Myers Squibb Company
F. Hoffman-La Roche Ltd
Galapagos NV
Lung Therapeutics, Inc.
Myriad Genetics, Inc
OptiKira LLC
Respivant Sciences GmbH
Veracyte, Inc

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Pulmonary fibrosis biomarkers market size was USD 4.1 billion in 2023 and is expected to reach over USD 6 billion by 2032 owing to the increasing advancements in biomarker discovery technology worldwide.

The imaging test segment recorded USD 1.7 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to imaging tests complementing biomarker analysis and providing a comprehensive view of disease status.

North America pulmonary fibrosis biomarkers industry recorded USD 1.7 billion in 2023 due to the presence of a highly advanced healthcare infrastructure with well-established hospitals, research institutions, and diagnostic laboratories in the region.

Biocartis NV, Biogen Inc, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd, Galapagos NV, Lung Therapeutics, Inc., Myriad Genetics, Inc, OptiKira LLC, Respivant Sciences GmbH, and Veracyte, Inc , are some of the major pulmonary fibrosis biomarkers companies worldwide.